Kolexia
Mansi Laura Oncologie médicale
Mansi Laura
Oncologie médicale
Hôpital Jean-Minjoz
Besançon, France
132 Activités
482 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein COVID-19 Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Carcinomes Métastase tumorale Récidive tumorale locale Néphrocarcinome Tumeurs du sein triple-négatives

Collaborateurs

Voir plus
Curtit Elsa
Curtit Elsa
Hôpital Jean-Minjoz, Besançon, France
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France
Bazan Fernando
Bazan Fernando
Le Mittan Annexe Du Hnfc, Montbéliard, France
Dobi Erion
Dobi Erion
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
Daiichi Sankyo
13 collaboration(s)
Dernière en 2023
Lilly
12 collaboration(s)
Dernière en 2023
Novartis
8 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ELAINEIII: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Essai Clinique (Sermonix Pharmaceuticals Inc.)   07 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   12 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   02 novembre 2023
EXOMA2: A Multicenter, Prospective, Multi-organ Study to Evaluate the Clinical Benefit of an Exome "Complex" Analysis Versus an Exome "Simple" Analysis to Help the Therapeutic Decision for the Precision Medicine
Essai Clinique (Centre Georges-François Leclerc)   20 octobre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
477P Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
OVHIPEC-2: Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
Essai Clinique (The Netherlands Cancer Institute)   07 septembre 2023
The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.
Frontiers in immunology   02 juin 2023